BioWorld2h
Switch Therapeutics nominates liver-sparing APOE RNAi therapy as development candidate for Alzheimer’s
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
BioWorld2h
Estrous cycle alters murine breast cancer response to chemotherapy
In breast cancer, neoadjuvant chemotherapy reduces the tumor before surgery. However, the response to this treatment does not ...
InnovationRx: FDA Issues New Guidance For AI In Medical Devices
This week, the FDA issued recommendations for streamlining the clearance process for AI-powered medical devices. The memo announcing this change recognizes that the utilization of AI in devices “is an ...
Drug acoramidis to treat rare heart disease approved by FDA
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...
The Pharma Letter3d
The week in pharma: action, reaction and insight – week to November 29
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Opinion | A Short Lesson in Drug Competition
Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new ...